Business Context and Reporting Period
Company: Werewolf Therapeutics, Inc. (Nasdaq: HOWL)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: An innovative biopharmaceutical company developing therapeutics to stimulate the immune system for cancer treatment using its proprietary PREDATOR platform. The company focuses on conditionally activated molecules (INDUKINE and INDUCER) that activate selectively in the tumor microenvironment. Key product candidates include WTX-124 (IL-2) and WTX-330 (IL-12).
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $1.9 million |
| Net Loss | $(60.8) million | $(70.5) million |
| Operating Expenses | $60.7 million | $75.5 million |
| Cash and Cash Equivalents (Year End) | $57.1 million | $111.0 million |
| Accumulated Deficit | $(475.4) million | $(414.6) million |
| Debt (K2HV Term Loan) | $28.2 million (net carrying value) | $26.1 million (net carrying value) |
| Stock-Based Compensation | $6.2 million | $8.8 million |
Note: The filing text does not provide specific gross profit or operating margin figures as the company has no product revenue.
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped to zero in 2025 from $1.9 million in 2024. The 2024 revenue was derived from a collaboration with Jazz Pharmaceuticals; the last performance obligation was completed in June 2024, and no further revenue was recognized in 2025.
- Expense Reduction: Total operating expenses decreased by $14.8 million (20%) year-over-year.
- R&D Expenses: Decreased by $11.6 million, primarily due to lower manufacturing costs ($10.8 million decrease) and personnel costs ($3.6 million decrease).
- G&A Expenses: Decreased by $3.2 million, driven by lower personnel and professional service costs.
- Cash Burn: Net cash used in operating activities increased slightly to $60.3 million in 2025 from $56.2 million in 2024, despite lower expenses, due to lower interest income and changes in working capital.
- Debt Structure: The company repaid its previous PWB term loan in May 2024 and replaced it with a new $30 million term loan from K2 HealthVentures (K2HV) with a higher effective interest rate (19.24% vs. previous rates).
Outlook, Risks, and Management Commentary
Strategic Review and Restructuring
In February 2026, the company adopted a restructuring plan to extend capital resources and initiated a strategic review process (advised by Piper Sandler) to explore alternatives such as a sale, merger, or asset divestiture. As part of this plan, the company executed a reduction in force affecting 64% of its workforce. Management estimates a one-time charge of approximately $4.1 million in Q1 2026 for severance and related benefits.
Liquidity and Going Concern
The filing explicitly states there is substantial doubt about the company's ability to continue as a going concern for at least twelve months from the date of issuance. With $57.1 million in cash as of December 31, 2025, management expects funds to be sufficient only through the fourth quarter of 2026. Additional funding is required to continue operations.
Clinical Progress
- WTX-124: Phase 1/1b trial data (Dec 2025) showed a 21% objective response rate in melanoma monotherapy and 30% in patients not primary resistant to immunotherapy. The FDA accepted 18 mg as the recommended dose.
- WTX-330: Phase 1b/2 trial initiated in Q1 2025. Dec 2025 data showed one confirmed partial response in metastatic gall bladder cancer.
Key Risks
- Capital Constraints: Inability to raise additional capital or complete a strategic transaction could force the company to curtail operations or liquidate.
- Delisting Risk: The company received a deficiency letter from Nasdaq on February 4, 2026, for failing to meet the $1.00 minimum bid price requirement. It has 180 days to regain compliance.
- Development Uncertainty: No products are approved for commercial sale; success depends on clinical trial outcomes and regulatory approvals.
Investor Verification Checklist
- Going Concern Status: Verify the timeline and progress of the strategic review process and the likelihood of securing additional capital before Q4 2026.
- Nasdaq Compliance: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement by August 3, 2026, to avoid delisting.
- Restructuring Costs: Confirm the actual cash outflow for the $4.1 million severance charge in Q1 2026 and any additional impairment charges.
- Debt Covenants: Review the K2HV Loan Agreement covenants to ensure compliance, particularly given the reduced workforce and potential changes in operating plans.
- Clinical Milestones: Track the completion dates for the WTX-124 Phase 1/1b trial (expected Q2 2026) and WTX-330 Phase 1b/2 trial (expected Q2 2026) as these are critical for potential partnerships.